Haemophilia A (F8, factor VIII deficiency) OMIM 306700

In Haemophilia A (F8, OMIM 306700), the master switch sits on the ↓ DOWN branch ([F] forced below); the healthy state is the ON well. The forced corrective direction is to raise s toward ON branch (polarity: supply). Classification: ✓ Recovers an existing standard. Direction only — no dose, no efficacy magnitude.

The disease maps to an R19 double-well whose corrective lever is read straight off the cusp (barrier 0.4326, γ 1.3155, spinodal 0.5807). The corrective direction is forced [F]; the agent names below are direction-concordant labels at grade [O] (no dose, no efficacy or safety magnitude). This is a research hypothesis offered to experts, not medical advice.

The emergence switch

The switch for Haemophilia A is an R19 double-well emerged from the real proximal-promoter DNA of F8. Its geometry is fixed by measured stiffness γ (never fitted); the numbers below are read directly off that cusp.

emergent axis
↓ DOWN [F]
healthy branch
ON
lesion
LOF_null
γ (stiffness)
1.3155
barrier
0.4326
spinodal
0.5807
s_on / s_off
1.1470 / -1.1470
fragility
0.78
corrective polarity
supply
forced direction
raise s toward ON branch

Chemistry feasibility (DIRECTION only [O]). small-molecule recrossing of the fold is geometrically plausible (barrier 0.4326 at neutral drive; lower barrier = smaller drive to supply). [O] -- no affinity/potency/dose/efficacy asserted.

The derived corrective lever

The cusp forces a corrective direction: raise s toward ON branch. This is the load-bearing output of the framework — it is [F] forced, and it is falsifiable. 2 lever families are derived; the lead is h-restore (drive modulator).

h-restore (drive modulator)sign: increasegeometric rank 0.78
Mechanism. supply / restore the positive drive (replace-or-agonise the missing competence)
Applies to. allele-agnostic (downstream/environmental tilt)
favoured when the switch is fragile -- a small drive shift recrosses the fold
Falsifier. If supplying/agonising F8 (raising the switch drive) does NOT move the DOWN [F] switch toward the healthy branch in a F8-deficient model, the h-restore(supply) lever is refuted for this axis.
gamma-restore (stabiliser / chaperone)sign: Nonegeometric rank 0.00
Mechanism. N/A
Applies to. none (honest exclusion)
EXCLUDED: null allele -- no product to stiffen
Falsifier. If a folding-stabiliser/chaperone does NOT re-deepen the healthy well for a residual F8 allele (no rescue that a null allele lacks), the gamma-restore lever is refuted; null alleles are excluded by construction.

Agents mapped onto the lever

✓ Agreement with established practice. The corrective direction derived here (raise s toward ON branch) independently matches an agent already in clinical use for this disease: FVIIIa-mimetic bispecific antibody (emicizumab); AAV F8 gene replacement (valoctocogene roxaparvovec); factor VIII protein replacement (recombinant / plasma-derived; extended-half-life Fc / PEG / single-chain). The geometry recovered known medicine — this is a validation signal for the logic, not a new treatment claim by this kit.
Existing agents whose known action is direction-concordant with the derived lever (status as pinned in the corpus; no dose, no efficacy magnitude).
agent (class)dir.statusphasemap
FVIIIa-mimetic bispecific antibody (emicizumab)
Oldenburg 2017 NEJM 377:809 (HAVEN 1, emicizumab); emicizumab (Hemlibra) FDA 2017 / EMA 2018 -- the cofactor-mimic class, active with or without FVIII inhibitors
increaseapproved4✓ in use
AAV F8 gene replacement (valoctocogene roxaparvovec)
Ozelo 2022 NEJM 386:1013 (GENEr8-1); valoctocogene roxaparvovec (Roctavian) FDA 2023 / EMA 2022 -- first approved haemophilia A gene therapy
increaseapproved4✓ in use
factor VIII protein replacement (recombinant / plasma-derived; extended-half-life Fc / PEG / single-chain)
recombinant factor VIII (octocog alfa) FDA 1992; extended-half-life rFVIIIFc (efmoroctocog alfa) and others approved
increaseapproved4✓ in use
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Direction-only candidate leads (corpus join)

Each lead is surfaced only because its known mechanism points the same way as the derived lever, and each comes with a source and a falsifier. None is a treatment.

octocog alfa (recombinant factor VIII)✓ recovered standarddir: increase · approved
Class. recombinant clotting factor VIII replacement
Mechanism. Infused to supply functional coagulation factor VIII directly into the clotting cascade, replacing the product the null F8 gene can no longer make. Direction: increase / restore the missing factor VIII competence. Allele scope: agnostic -- replaces the downstream protein irrespective of the F8 variant. Pathway-specific to factor VIII supply (mapped to haemophilia A). Factor concentrate is the universally established standard; the geometry's supply direction recovers it.
✓ This is a rediscovery. Factor VIII replacement is the universally established standard of care for haemophilia A; the supply-direction logic recovered established practice.
Safety (qualitative; no magnitude). long-established replacement-factor class; inhibitor-development and infusion-reaction signals noted on label (qualitative; no magnitude)
Falsifier. If octocog alfa (recombinant factor VIII) (a pathway supply/increase agent) does NOT move the DOWN [F] switch toward the healthy branch in a F8-deficient model, the h-restore(supply) direction is refuted for octocog alfa (recombinant factor VIII) here.
Source: Haemophilia A, GeneReviews; Mannucci 2001 NEJM 344:1773
⚠ Mechanism-direction only — do not self-administer; no dose (unvalidated; set by a physician / national authority); not an approved use.

Evidence & provenance

What is reproduced vs. cited for this page.
elementgradebasis
R19 switch & cusp geometry (this page)[V] verifiedemerged from measured promoter γ of F8; deterministic, 2×sha256 identical
corrective direction[F] forcedforced by the cusp sign; falsifiable (see lever falsifiers)
mapped agents / leads[O] opendirection-concordance only; corpus-pinned (2026-06-21); no dose, no efficacy/safety magnitude

Reading the agent column. VALIDATION SIGNAL -- the agent is already approved / established standard for this disease, so the direction logic recovered known clinical practice. Not a new claim by this kit. GENUINE HYPOTHESIS -- no approved indication for this disease; the direction match is a direction-only, untested [O] lead. Basis field grades the evidence (investigational here / in a related condition / off-label / speculative).